| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23f5e367b9090dcf9312517fd445dad1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6831
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abc7a67cd60cff7b0d13d2e8616d1f02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de3d9bcb6a2958ae53b29f3ae712034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96f00fac8575e2f9ac70211be84a9f86 |
| publicationDate |
2022-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022062339-A1 |
| titleOfInvention |
Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy |
| abstract |
The invention provides methods of depleting CD45+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD45 antibody drug conjugates (ADCs) are administered as a conditioning regimen to a human patient receiving autologous or allogeneic CAR expressing immune cells such that the CAR expressing immune cells are accepted by the human patient. Compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer. |
| priorityDate |
2019-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |